NASDAQ:MOLN Molecular Partners (MOLN) Stock Price, News & Analysis $4.05 +0.14 (+3.58%) Closing price 10/2/2026 02:01 PM EasternExtended Trading$4.04 0.00 (-0.12%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Molecular Partners Stock (NASDAQ:MOLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Molecular Partners alerts:Sign Up Key Stats Today's Range$3.91▼$4.0850-Day Range$3.77▼$4.6152-Week Range$3.53▼$5.36Volume1,848 shsAverage Volume1,257 shsMarket Capitalization$163.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.38Consensus RatingHold Company Overview Molecular Partners AG is a clinical-stage biotechnology company based in Zurich, Switzerland. The company develops medicines using its proprietary DARPin platform, which is based on designed ankyrin repeat proteins. These engineered proteins are intended to bind selectively to therapeutic targets and can be assembled into multi-specific molecules designed to address complex diseases. Molecular Partners focuses primarily on oncology and other serious diseases, including immunological and infectious conditions. Its research and development programs are designed to modulate the tumor microenvironment, engage immune cells, and target disease-related proteins. The company’s pipeline has included investigational oncology candidates such as MP0310 and MP0533, as well as ensovibep, an antiviral DARPin developed for coronavirus infections. Founded in 2004, Molecular Partners conducts research and clinical development from Switzerland and collaborates with pharmaceutical and biotechnology companies to advance its drug candidates. The company is listed on the Nasdaq Global Select Market under the symbol MOLN and maintains an international focus through its clinical development activities and strategic partnerships.AI Generated. May Contain Errors. Read More Molecular Partners Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreMOLN MarketRank™: Molecular Partners scored higher than 53% of companies evaluated by MarketBeat, and ranked 459th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingMolecular Partners has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMolecular Partners has a consensus price target of $8.38, representing about 106.8% upside from its current price of $4.05.Amount of Analyst CoverageMolecular Partners has only been the subject of 2 research reports in the past 90 days.Read more about Molecular Partners' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Molecular Partners are expected to grow in the coming year, from ($1.28) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Partners is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Partners is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Partners has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Molecular Partners' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Molecular Partners has been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Molecular Partners has recently decreased by 0.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMolecular Partners does not currently pay a dividend.Dividend GrowthMolecular Partners does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Molecular Partners insiders have not sold or bought any company stock.Percentage Held by Insiders5.93% of the stock of Molecular Partners is held by insiders.Percentage Held by Institutions26.55% of the stock of Molecular Partners is held by institutions.Read more about Molecular Partners' insider trading history. Receive MOLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOLN Stock News HeadlinesMolecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash BaseAugust 26, 2026 | theglobeandmail.comMolecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyAugust 25, 2026 | globenewswire.comElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no driver in major U.S. cities. Veteran tech investor James Altucher says Musk is applying the same playbook to a new project he calls his infinite money glitch, expected to launch October 21. Altucher, who has tracked tech breakthroughs for nearly four decades, calls this the biggest one he has ever covered.October 4 at 1:00 AM | Paradigm Press (Ad)Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research ConferenceJuly 15, 2026 | globenewswire.comLifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)July 12, 2026 | theglobeandmail.comMolecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin RadiotherapeuticsJuly 6, 2026 | globenewswire.comMolecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712July 2, 2026 | globenewswire.comMolecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1May 30, 2026 | globenewswire.comSee More Headlines MOLN Stock Analysis - Frequently Asked Questions How have MOLN shares performed this year? Molecular Partners' stock was trading at $4.4450 on January 1st, 2026. Since then, MOLN stock has decreased by 8.9% and is now trading at $4.05. How were Molecular Partners' earnings last quarter? Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) issued its earnings results on Tuesday, August, 25th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01. When did Molecular Partners IPO? Molecular Partners (MOLN) raised $64 million in an IPO on the week of June 14th 2021. The company issued 3,000,000 shares at a price of $21.25 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Molecular Partners? Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Molecular Partners own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE). Company Calendar Last Earnings8/25/2026Today10/04/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (25m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MOLN's financial health is in the Red zone, according to TradeSmith. MOLN has been in this zone for over 25 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MOLN CIK1745114 Webwww.molecularpartners.com Phone41-44-755-7700FaxN/AEmployees134Year Founded2004Price Target and Rating Average Price Target for Molecular Partners$8.38 High Price Target$13.00 Low Price Target$3.75 Potential Upside/Downside+106.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.36% Return on Assets-54.82% Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.27 Sales & Book Value Annual Sales$5.65 million Price / Sales28.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book1.69Miscellaneous Outstanding Shares40,380,000Free Float37,981,000Market Cap$163.54 million OptionableNot Optionable Beta1.11 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:MOLN) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredFree Stock: Economist calls it “the world’s most important machine.”Nvidia's most expensive chip component isn't made by Nvidia. Jeff Brown, former semiconductor executive, says ...Brownstone Research | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
